ArticleCureus2026
Allopurinol-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Case Report and Review of the Published Evidence From India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a 58-year-old hypertensive female who developed generalized erythematous, pruritic skin lesions approximately 35 days after initiating allopurinol (100 mg twice daily) for a provisional diagnosis of gout. Dermatological examination revealed diffuse erythematous to hyperpigmented scaly plaques involving the face, trunk, groin, buttocks, and extremities. Laboratory investigations demonstrated marked eosinophilia (30%; absolute eosinophil count of 880 cells/mm³), persistent leukocytosis, transient thrombocytopenia (140,000/mm³), acute kidney injury with elevated blood urea (102-116 mg/dL) and serum creatinine (1.8-3.8 mg/dL), and hepatic dysfunction with elevated alanine aminotransferase (130 IU/L) and alkaline phosphatase (179 U/L). Infectious and autoimmune causes were excluded, and a RegiSCAR score of 7 established a definite diagnosis of DRESS syndrome. Allopurinol was immediately discontinued, and the patient was treated with intravenous hydration, systemic corticosteroids, antihistamines, and supportive care, followed by a gradual tapering of prednisolone. The patient showed complete clinical recovery without recurrence. This case highlights the importance of early recognition of allopurinol-induced DRESS syndrome, prompt withdrawal of the offending drug, timely initiation of systemic corticosteroid therapy, and close monitoring of renal and hepatic involvement to achieve favorable clinical outcomes. It also underscores the value of pharmacovigilance and adverse drug reaction reporting in improving medication safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.